AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
BRIDGEWATER, N.J., May 01, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 4:10 p.m. EDT.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
